Abstract
Genetic differences in the metabolism of carcinogens may codetermine individual predisposition to cancer. Cytochrome P-4501A1 (CYP1A1) metabolically activates precarcinogens in cigarette smoke, such as benzo(a)pyrene, which is also an inducer of CYP1A1. Two point mutations have been reported, m1 in the 3′-flanking region (6235T to C), and m2 within exon 7 (4889A to G), the latter leading to an isoleucine to valine exchange. In the Japanese population ml and m2 are correlated with lung cancer, suggesting an increased susceptibility to cigarette smoking related lung cancer. We studied 142 lung cancer and 171 reference patients in an ethnically homogeneous German group for m1 and m2 mutations by restriction fragment length polymorphism and allele-specific polymerase chain reaction, respectively. No statistically significant difference was found in the distribution of m1 alleles between lung cancer and controls; the frequency was 8.5% and 7.3% of the alleles, respectively (odds ratio = 1.17). A trend to an overrepresentation of ml alleles was observed among 52 squamous cell carcinoma patients (odds ratio = 1.65). In contrast, the frequency of m2 alleles in lung cancer patients was twofold higher (6.7%) than in the reference group (3.2%; odds ratio = 2.16; 95% confidence limits 0.96–5.11, P = 0.033); the odds ratio of m2 alleles in squamous cell carcinoma was 2.51 (95% confidence limits 0.85–7.05, P = 0.05). There was a close genetic linkage of m2 to m1 (10 of 11 reference patients), but a significantly higher number of cancer patients showed no linkage compared to the controls (odds ratio = 8.89, 95% confidence limits 0.83–433, P = 0.04). Thus no association was found between presence of ml alleles and lung cancer, but, in contrast, m2 alleles proved as a hereditary risk factor, especially if not linked with m1 alleles.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- Ah:
-
aryl hydrocarbon
- CYP1A1:
-
cytochrome P4501A1
- CYP1A1 :
-
CYP1A1 gene
- PCR:
-
polymerase chain reaction
- PY:
-
pack years
- RFLP:
-
restriction fragment length polymorphism
References
Bale AE, Nebert DW, McBride OW (1987) Subchromosomal localization of the dioxin-inducible P 1-450 locus (CYP1) and description of two RFLPs detected with a 3′ P 1-450 cDNA probe. Cytogenet Cell Genet 46:574–5751
Brockmöller J, Kerb R, Drakoulis N, Nitz M, Roots I (1993) Genotype and phenotype of glutathione S-transferase class μ isoenzymes μ and ψ in lung cancer patients and controls. Cancer Res 53:1004–1011
Drakoulis N, Beland M, Roots I (1991) Determination of arylamine N-acetyltransferase genotype in humans. Naunyn-Schmiedebergs Arch Pharmacol 344 [Suppl]: R88
Fujii-Kuriyama Y, Imataka H, Sogawa K, Yasumoto KI, Kikuchi Y (1992) Regulation of CYP1A1 expression. FASEB J 6:706–710
Gonzalez FJ, Liu SY, Yano M (1993) Regulation of cytochrome P450 genes: molecular mechanisms. Pharmacogenetics 3:51–57
Guengerich FP, Shimada T (1991) Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4:391–407
Hayashi S, Watanabe J, Nakachi K, Kawajiri K (1991) Genetic linkage of lung cancer-associated MspI polymorphism with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem 110:407–411
Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Sorsa M, Vainio H (1992) Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. Pharmacogenetics 2:259–263
Ingelman-Sundberg M, Johansson I, Persson I, Yue QY, Dahl ML, Bertilsson L, Sjögvist F (1992) Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer. Pharmacogenetics 2:264–271
Jaiswal AK, Gonzalez FJ, Nebert DW (1985) Human P1-450 gene sequence and correlation of mRNA with genetic differences in benzo(a)pyrene metabolism. Nucleic Acids Res 13:4503–4520
Kawajiri K, Watanabe J, Gotoh O, Tagashira Y, Sogawa K, Fujii-Kuriyama Y (1986) Structure and drug inducibility of the human cytochrome P-450c gene. Eur J Biochem 159:219–225
Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe I (1990) Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of cytochrome P4501A1 gene. FEBS Lett 263:131–133
Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S (1993) The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol 14:77–87
Kouri RE, McKinney CE, Slomianry DJ, Snodgrass DR, Wray NP, McLemore TL (1982) Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res 42:5030–5037
McLemore TL, Adelberg S, Liu MC, McMahon NA, Yu SJ, Hubbard WC, Czerwinski M, Wood TG, Storeng R, Lubet RA, Eggleston JC, Boyd MR, Hines RN (1990) Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke induced gene expression in normal lung tissue and for pulmonary carcinomas. J Natl Cancer Inst 82:1333–1339
Nakachi K, Imai K, Hayashi S, Watanabe J, Kawajiri K (1991) Genetic susceptibility to squamous-cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 51:5177–5180
Nebert DW, Petersen DD, Puga A (1991) Human AH locus polymorphism and cancer: inducibility of CYP1A1 and other genes by combustion products and dioxin. Pharmacogenetics 1:68–78
Petersen DD, McKinney CE, Ikeya K, Smith HH, Bale AE, McBride OW, Nebert DW (1991) Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet 48:720–725
Roots I, Drakoulis N, Ploch M, Heinemeyer G, Loddenkemper R, Minks T, Nitz M, Otte F, Koch M (1988) Debrisoquine hydroxylation phenotype, acetylation phenotype, and AB0 blood groups as genetic host factors of lung cancer risk. Klin Wochenschr 66 [Suppl XI]:87–97
Roots I, Brockmöller J, Drakoulis N, Loddenkemper R (1992) Mutant genes of cytochrome P-450IID6, glutathione S-transferase class mu, and arylamine N-acetyltransferase in lung cancer patients. Clin Investig 70:307–319
Roots I, Drakoulis N, Brockmöller J (1992) Polymorphic enzymes and cancer risk: concepts, methodology and data review. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon, New York, pp 815–841
Rost KL, Brösicke H, Brockmöller J, Scheffler M, Helge H, Roots I (1992) Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 52:170–180
Sambrock J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
Schlesselman JJ (1974) Sample size requirements in cohort and case-control studies of disease. Am J Epidemiol 99:381–384
Shields PG, Sugimura H, Caporaso NE, Petruzelli SF, Bowman ED, Trump BF, Weston A, Harris CC (1992) Polycyclic aromatic hydrocarbon-DNA adducts and the CYP1A1 restriction fragment length polymorphism. Environ Health Perspect 98:191–194
Spurr NK, Gough AC, Stevenson K, Wolf CR (1987) MspI-polymorphism detected with a cDNA probe for the P-450 I family on chromosome 15. Nucleic Acids Res 15:5901
Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401–407
Tefre T, Ryberg D, Haugen A, Nebert DW, Skaug V, Brøgger A, Borresen AL (1991) Human CYP1A1 (cytochrome P1450) gene: lack of association between the MspI restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1:20–25
Author information
Authors and Affiliations
Additional information
Correspondence to: N. Drakoulis
Rights and permissions
About this article
Cite this article
Drakoulis, N., Cascorbi, I., Brockmöller, J. et al. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region. Clin Investig 72, 240–248 (1994). https://doi.org/10.1007/BF00189321
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00189321